SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 36,241 Shares of Company Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 36,241 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $24.80, for a total value of $898,776.80. Following the completion of the transaction, the senior vice president owned 40,167 shares of the company’s stock, valued at $996,141.60. This represents a 47.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

SiBone Price Performance

SIBN opened at $24.24 on Friday. SiBone has a 12-month low of $11.48 and a 12-month high of $25.92. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $1.08 billion, a P/E ratio of -78.19 and a beta of 0.64. The stock has a 50-day moving average price of $19.81 and a 200-day moving average price of $16.59.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. The business had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. Equities analysts predict that SiBone will post -0.34 earnings per share for the current fiscal year.

More SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

Wall Street Analyst Weigh In

SIBN has been the subject of a number of research analyst reports. UBS Group boosted their price target on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Truist Financial increased their price target on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. TD Cowen boosted their target price on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC reduced their price objective on SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Institutional Trading of SiBone

A number of institutional investors have recently bought and sold shares of SIBN. First Light Asset Management LLC lifted its position in shares of SiBone by 51.8% during the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after buying an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC lifted its holdings in shares of SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after buying an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY grew its stake in SiBone by 113.3% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after purchasing an additional 598,300 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after purchasing an additional 182,465 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in SiBone by 101.6% during the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after purchasing an additional 238,219 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.